- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Carboplatin, Nab-paclitaxel, GM-CSF, Trastuzumab, Bevacizumab
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Orange, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,982
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cushings Disease, Cushing Disease
- Interventions
- LCI699
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more
- Conditions
- Osteoporosis
- Interventions
- Human parathyroid hormone [hPTH-(1-34)], alendronate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- TransCon PTH, Placebo
- Combination Product
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
- Conditions
- Insulin Resistance
- Interventions
- A= Yes Breakfast, B=No Breakfast
- Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 13 Years to 18 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Growth Hormone Deficiency
- Interventions
- Somavaratan
- Drug
- Lead sponsor
- Versartis Inc.
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Menlo Park, California
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone Acetate, Prednisone, LHRHa
- Drug
- Lead sponsor
- Cougar Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Major Depressive Disorder
- Interventions
- Cytomel (liothyronine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 6
- States / cities
- Duarte, California • Loma Linda, California • Orange, California + 2 more
- Conditions
- Breast Cancer
- Interventions
- RGT-419B, RGT-419B in combination with hormonal therapy
- Drug
- Lead sponsor
- Regor Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more
- Conditions
- Insulin-like Growth Factor-1 Deficiency
- Interventions
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Osteopenia, Osteoporosis
- Interventions
- Soy isoflavones, Extract tablets
- Dietary Supplement
- Lead sponsor
- Iowa State University
- Other
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 224 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Davis, California • Ames, Iowa
- Conditions
- Metastatic Breast Cancer, Hormone Receptor Positive
- Interventions
- Palbociclib, Tamoxifen, Fulvestrant
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sorafenib, Letrozole
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
- Conditions
- Prostate Cancer
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Geriatric Oncology Consortium
- Other
- Eligibility
- 65 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV Infections
- Interventions
- Medroxyprogesterone acetate, Estradiol
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Prostate Cancer
- Interventions
- GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more
- Conditions
- Breast Cancer
- Interventions
- Pembrolizumab, Fulvestrant
- Drug
- Lead sponsor
- Nancy Chan, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 5
- States / cities
- Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more
- Conditions
- Breast Cancer
- Interventions
- Vandetanib, Anastrozole
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
- Interventions
- White Wine, Grape Juice
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 21 Years to 90 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Interventions
- saracatinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Dementia Syndromes
- Interventions
- Estrogen hormone therapy, Estrogen plus progesterone hormone therapy, Placebo
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 65 Years to 79 Years · Female only
- Enrollment
- 7,525 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2008
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Interventions
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy
- Drug · Procedure
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas